TP53 and prostate cancer: Inasmuch as androgen-independent prostate cancer cells with non-functional p53 are able to quite easy cope with damages caused by ROS producing agents and ROS can even participate in positive selection of resistant PGCCs with some pluripotent characteristics, prostate cancer therapies based on ROS producing agents could be a misleading concept.